Latest

Integrated biotech–CDMO partnerships are becoming critical as fusion protein complexity pushes developers to align discovery and manufacturing earlier.

Survey results show a shift in pharma industry sentiment from optimism to caution as rising insecurity offsets high satisfaction and intellectual engagement.

The European Commission’s approval of GSK’s Arexvy for adults 18 years and older expands the respiratory syncytial virus vaccine market and signals broader adoption of adult immunization strategies.

Green chemistry is emerging as a strategic lever for biopharma manufacturing, enabling safer processes, efficiency gains, and long-term competitiveness.

Biopharma manufacturing faces a global workforce crisis, driving adoption of continuous upstream automation to protect and scale capacity, says Eric Langer of BioPlan Associates, in the continuation of his industry outlook.

The decision is based on President Trump’s executive order issued last year.

Mendra’s launch highlights the growing use of AI to improve patient identification, clinical execution, and commercialization in rare disease programs.

Next-gen antibody R&D is shifting to multifunctional modalities driven by manufacturing scale and regulatory acceleration.

EU regulators clear Otsuka’s antisense injectable to prevent hereditary angioedema attacks, reinforcing momentum for RNA-based rare disease medicines.

GSK’s purchase of RAPT underscores growing biopharma focus on durable biologics designed to reduce dosing burden in food allergy and immunology care.

A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.

As adenovirus vectors continue to evolve into versatile platforms for vaccines and complex therapeutics, advances in vector design and formulation are proving critical to ensuring manufacturing consistency, therapeutic potency, and patient-ready delivery at scale.

In 2026, AI and automation are anticipated to solve talent gaps and economic shifts to drive resilient drug discovery and manufacturing.